MX341660B - Agonista del receptor de ghrelina para el tratamiento de caquexia. - Google Patents
Agonista del receptor de ghrelina para el tratamiento de caquexia.Info
- Publication number
- MX341660B MX341660B MX2012009774A MX2012009774A MX341660B MX 341660 B MX341660 B MX 341660B MX 2012009774 A MX2012009774 A MX 2012009774A MX 2012009774 A MX2012009774 A MX 2012009774A MX 341660 B MX341660 B MX 341660B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- dyscrasia
- treatment
- pharmaceutical composition
- receptor agonist
- Prior art date
Links
- 102000000393 Ghrelin Receptors Human genes 0.000 title 1
- 108010016122 Ghrelin Receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el uso de un compuesto de la presente invención o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal, para la manufactura de un medicamento para el tratamiento de caquexia. La invención también se refiere con un método para el tratamiento de caquexia, el cual comprende la administración del compuesto de la presente invención, o una composición farmacéutica que comprende el mismo a un ser humano o a un animal. La invención además se refiere al uso de dicho compuesto, o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal, en combinación con uno o más segundos agentes activos. Más aún, la invención se refiere a una composición farmacéutica y a un kit que comprende el compuesto de la presente invención o una sal farmacéuticamente aceptable de éste, para el tratamiento de la caquexia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010043484 | 2010-02-26 | ||
| PCT/JP2011/054556 WO2011105611A1 (ja) | 2010-02-26 | 2011-02-28 | 悪液質を治療するためのグレリン受容体作動物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012009774A MX2012009774A (es) | 2012-10-05 |
| MX341660B true MX341660B (es) | 2016-08-29 |
Family
ID=44507004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009774A MX341660B (es) | 2010-02-26 | 2011-02-28 | Agonista del receptor de ghrelina para el tratamiento de caquexia. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10975070B2 (es) |
| EP (1) | EP2540721B1 (es) |
| JP (1) | JPWO2011105611A1 (es) |
| KR (1) | KR20120131183A (es) |
| CN (1) | CN102762564B (es) |
| BR (1) | BR112012020377B1 (es) |
| CA (1) | CA2789750C (es) |
| ES (1) | ES2615731T3 (es) |
| FR (1) | FR23C1048I1 (es) |
| MX (1) | MX341660B (es) |
| RU (1) | RU2012141061A (es) |
| WO (1) | WO2011105611A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2906041A4 (en) * | 2012-09-27 | 2016-10-26 | Aratana Therapeutics Inc | COMPOSITIONS AND METHODS FOR USE IN A CAPACITY CONNECTOR |
| BR112015029586B1 (pt) * | 2013-05-28 | 2022-05-03 | Raqualia Pharma Inc | Formas polimorfas |
| TW201625613A (zh) * | 2014-10-31 | 2016-07-16 | 拉夸里亞創藥股份有限公司 | 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物 |
| CA2974012C (en) | 2015-01-28 | 2020-08-18 | Aratana Therapeutics, Inc. | Compositions and methods for chronic use of a weight-gaining compound |
| CN120081796A (zh) * | 2020-09-22 | 2025-06-03 | 庆北大学校产学协力团 | 作为胃促生长素受体激动剂的三唑化合物的用途 |
| CN115778960B (zh) * | 2022-08-19 | 2024-09-20 | 广州六顺生物科技有限公司 | 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用 |
| CN119868339A (zh) * | 2025-01-23 | 2025-04-25 | 北京珺泰科技有限公司 | 淫羊藿素在治疗肿瘤恶病质的药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997984A (en) | 1989-12-19 | 1991-03-05 | Shawa Denko K.K. | Process for preparation of N-(α-alkoxyethyl)-carboxylic acid amide |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| EP1781311A4 (en) * | 2004-08-18 | 2010-02-17 | Elixir Pharmaceuticals Inc | WACHSTUMSHORMONSEKRETAGOGE |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| KR20090112720A (ko) * | 2007-02-13 | 2009-10-28 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법 |
| WO2008153027A1 (ja) | 2007-06-11 | 2008-12-18 | Takeda Pharmaceutical Company Limited | ピロロキノリン誘導体およびその用途 |
| WO2009063993A1 (ja) * | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| WO2009139340A1 (ja) * | 2008-05-12 | 2009-11-19 | 武田薬品工業株式会社 | ピラゾール化合物 |
| EP2906041A4 (en) | 2012-09-27 | 2016-10-26 | Aratana Therapeutics Inc | COMPOSITIONS AND METHODS FOR USE IN A CAPACITY CONNECTOR |
-
2011
- 2011-02-28 ES ES11747565.7T patent/ES2615731T3/es active Active
- 2011-02-28 RU RU2012141061/04A patent/RU2012141061A/ru not_active Application Discontinuation
- 2011-02-28 CA CA2789750A patent/CA2789750C/en active Active
- 2011-02-28 JP JP2012501911A patent/JPWO2011105611A1/ja active Pending
- 2011-02-28 EP EP11747565.7A patent/EP2540721B1/en active Active
- 2011-02-28 BR BR112012020377-0A patent/BR112012020377B1/pt active IP Right Grant
- 2011-02-28 WO PCT/JP2011/054556 patent/WO2011105611A1/ja not_active Ceased
- 2011-02-28 MX MX2012009774A patent/MX341660B/es active IP Right Grant
- 2011-02-28 CN CN201180009948.8A patent/CN102762564B/zh active Active
- 2011-02-28 US US13/580,479 patent/US10975070B2/en active Active
- 2011-02-28 KR KR1020127024117A patent/KR20120131183A/ko not_active Withdrawn
-
2021
- 2021-03-02 US US17/189,552 patent/US20210179613A1/en not_active Abandoned
-
2023
- 2023-12-18 FR FR23C1048C patent/FR23C1048I1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102762564B (zh) | 2015-09-30 |
| US10975070B2 (en) | 2021-04-13 |
| BR112012020377A2 (pt) | 2016-05-10 |
| WO2011105611A1 (ja) | 2011-09-01 |
| MX2012009774A (es) | 2012-10-05 |
| HK1174615A1 (en) | 2013-06-14 |
| JPWO2011105611A1 (ja) | 2013-06-20 |
| ES2615731T3 (es) | 2017-06-08 |
| EP2540721A1 (en) | 2013-01-02 |
| BR112012020377B1 (pt) | 2019-10-08 |
| CA2789750A1 (en) | 2011-09-01 |
| RU2012141061A (ru) | 2014-04-10 |
| CA2789750C (en) | 2018-03-06 |
| BR112012020377A8 (pt) | 2018-01-02 |
| KR20120131183A (ko) | 2012-12-04 |
| CN102762564A (zh) | 2012-10-31 |
| EP2540721A4 (en) | 2013-08-07 |
| FR23C1048I1 (fr) | 2024-01-19 |
| EP2540721B1 (en) | 2016-12-14 |
| US20210179613A1 (en) | 2021-06-17 |
| US20120322821A1 (en) | 2012-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| WO2011157416A3 (de) | Transdermale verabreichung von memantin | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| WO2008051527A3 (en) | Sustained release of agents for localized pain management | |
| MX2008011020A (es) | Compuestos de receptor sigma. | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis | |
| WO2012125871A3 (en) | Aconitine compounds, compositions, uses, and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |